Deals, Development and Manufacturing

Novartis Invests in UK’s Largest Health Research Program

April 03, 2024

Our Future Health, a health research program in the UK, has welcomed Novartis as a new industry partner.

Univercells and Andelyn Biosciences Form Separate Drug Development Partnerships

March 28, 2024

Univercells and Altamira Therapeutics are collaborating on nanoparticle-delivered mRNA vaccines, while Andelyn Biosciences and Grace Science are partnering on novel therapies for NGLY1 deficiency.

AbbVie Gains Landos Biopharma and Full FDA Approval for ADC Product

March 28, 2024

The Landos acquisition adds a lead asset in autoimmune and inflammatory disease to AbbVie's portfolio, while the company's ADC, ELAHERE, gets full FDA approval.

Roche Sells Large-Scale Biologics Manufacturing Site in US to Lonza for $1.2 Billion

March 26, 2024

The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.

AstraZeneca to Acquire Amolyt Pharma in Deal Worth Potentially $1.05 Billion

March 22, 2024

AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

March 16, 2024

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

March 14, 2024

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

March 07, 2024

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

March 07, 2024

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

March 06, 2024

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.